Novo Nordisk's Balancing Act: A Failed Trial, a Legal Offensive, and the Weight of a Price Cut

Novo Nordisk faces clinical setback, legal battle with Lilly, and US price cuts as Q2 results may determine stock's technical fate.

The numbers due out on Wednesday will do more than just update Novo Nordisk's balance sheet — they will determine whether the Danish pharma giant can hold the line against a confluence of pressures that have left its shares hovering near a critical technical threshold. With the stock trading at roughly 41 euros, the company finds itself squeezed between a disappointing late-stage trial readout, an escalating legal battle with its biggest rival, and a looming price reset in its most important market.

A Clinical Setback That Stings but Doesn't Bite

The most immediate source of investor anxiety came on Friday, July 31, when the phase 3 ZEUS trial failed to meet its primary endpoint. Ziltivekimab, an IL-6 antibody being developed for patients with atherosclerotic cardiovascular disease and chronic kidney impairment, showed a hazard ratio of 0.99 against placebo — effectively no benefit in reducing major cardiovascular events.

Morningstar analyst Karen Andersen called the outcome disappointing but cautioned against overreaction. The drug was never expected to contribute more than a small slice of group revenue before 2035, and management has confirmed its 2026 operating profit guidance remains intact. Still, the miss eliminates a potential growth driver outside the obesity franchise, and a non-cash impairment charge will land in the third quarter.

Fighting on a Second Front

Novo Nordisk is not taking the setback lying down. On July 21, the company filed suit against Eli Lilly in the US District Court for the District of New Jersey, alleging misleading advertising for Lilly's obesity treatments, including the recently launched Foundayo. The complaint centers on claims that Lilly's marketing compares the highest doses of its own products against lower doses of Novo's medicines, relying on outdated clinical data.

The litigation underscores just how fierce competition has become in a weight-loss market projected to exceed $100 billion by the end of the decade. Novo still holds a strong hand with its oral Wegovy pill, which launched on January 5 and has already surpassed three million prescriptions. But competitive pressure has intensified noticeably since the spring.

The Price-Volume Equation

The bigger strategic question hanging over Wednesday's report concerns pricing. Starting January 1, 2027, Novo Nordisk will slash US list prices for Wegovy by roughly 50 percent and Ozempic by about 35 percent, unifying both at $675. The central issue for investors: can prescription volumes grow quickly enough to offset the revenue hit?

First-quarter figures offered a mixed preview. Revenue rose 6 percent on a currency-adjusted basis, with EUCAN and APAC leading the way while emerging markets and China dragged. Obesity sales grew a robust 44 percent currency-adjusted, though lower realized prices ate into the gains. The GLP-1 diabetes business actually contracted 1 percent.

Technical Crossroads

The chart tells a story of a market that cannot make up its mind. The stock sits just above its 200-day moving average of 40.34 euros — a level widely watched as critical support. A decisive break below that mark would darken the technical picture considerably. Above, the 50-day average of 41.01 euros offers the first resistance.

The share price has recovered more than 36 percent from its March 2 low of 30.25 euros, yet remains roughly 25 percent below its January peak of 54.86 euros. For 2026, the stock is still down 6.44 percent, with last week alone bringing a decline of 7.75 percent. The relative strength index sits at a neutral 43.5, while annualized volatility has climbed to a lofty 34.28 percent — hardly the profile of a stock in calm waters.

Divergent Analyst Views

Wall Street remains split on the outlook. Argus Research and UBS have both downgraded the stock recently, while TD Cowen maintains a notably more bullish price target. That divergence mirrors the central debate: whether the 2027 price cuts will be offset by volume growth, or whether margin pressure will dominate.

Consensus estimates for the second quarter point to earnings per share of $0.77 on revenue of roughly $10.89 billion. Beyond the headline numbers, investors will be watching prescription trends for the oral Wegovy pill — continued momentum there could help push the ZEUS disappointment to the background.

What Wednesday Must Deliver

The earnings release on August 5 will need to address three questions head-on. First, how does management frame the relationship between the planned US price reductions and volume growth in the obesity segment? Second, what is the latest on the Denecimig approval process — the hemophilia candidate for which a filing was submitted to the FDA in September 2025, and which showed promising interim FRONTIER4 data at the ISTH congress? Third, can the company reaffirm its full-year guidance despite the clinical setback?

The stock's fate may hinge on the answers. Hold above the 50-day average and the recovery from March's low looks increasingly durable. Slip below the 200-day line and the bears regain control, with the January high of 54.86 euros receding further into the distance and the March low of 30.25 euros coming back into view. Wednesday's report will determine which path the shares take.